Article
Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.
Cancer chemotherapy and pharmacology - 1 Feb 2010
Pithavala Y K, Tortorici M, Toh M, Garrett M, Hee B, Kuruganti U, Ni G, Klamerus K J
Abstract excerpt
PURPOSE: Axitinib, a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2, 3, is metabolized by cytochrome P450 3A4 and glucuronidation. This study evaluated the effect of rifampin, a potent inducer of drug-metabolizing enzymes, on axitinib plasma pharmacokinetics. Equal numbers of Japanese and Caucasian subjects were enrolled to assess the potential differences in axitinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.